Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

NCT02203903 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS

Interventions

BIOLOGICAL: Tumor associated antigen lymphocytes (TAA-T)

Sponsor

Catherine Bollard

Collaborators

[object Object]
[object Object]